etidronate and Bone Loss, Osteoclastic studies

Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.

Research Excerpts

Excerpt	Relevance	Reference
"The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis."	9.11	Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004)
"The results suggest that etidronate could prevent high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases."	9.11	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. ( Nakayamada, S; Okada, Y; Saito, K; Tanaka, Y, 2004)
"The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures."	9.10	Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."	7.78	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro."	7.73	Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. ( Nagashima, M; Shue, G; Yamamoto, K; Yoshino, S, 2006)
"Etidronate was effective at inhibiting bone resorption and destruction in study patients with RA, while not increasing BAP concentrations; and a correlation was observed between the concentration of DPD and IL-6, indicating the antiinflammatory effect of etidronate."	6.71	Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. ( Hasegawa, J; Katsumata, S; Nagashima, M; Nishijima, T; Yamamoto, M; Yoshino, S, 2003)
" Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures."	6.18	Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997)
"EHL of vesical calculi was again performed in April 2004."	5.33	Recurrent vesical calculi, hypercalciuria, and biochemical evidence of increased bone resorption in an adult male with paraplegia due to spinal cord injury: is there a role for intermittent oral disodium etidronate therapy for prevention of calcium phosph ( Buczynski, AZ; Fraser, WD; Grases, F; Heilberg, IP; Hughes, PL; Jonsson, O; Kohri, K; Schurch, B; Sett, P; Singh, G; Soni, BM; Tozawa, K; Vaidyanathan, S; Watson, ID; Wyndaele, JJ; Yasui, T, 2005)
"It is attributed to an increase in bone resorption and diminished bone formation characterized clinically by elevated serum calcium levels, hypercalciuria, increased risk of urinary lithiasis, and renal failure."	5.29	Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. ( Cross, LL; Meythaler, JM; Tuel, SM, 1993)
"Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption."	5.29	Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995)
"Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight)."	5.28	Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. ( LeBlanc, AD; Mallette, LE; Mechanick, JI; Pool, JL, 1989)
"The aim of this study was to assess the effects of the antiresorptive treatments of alendronate (ALN), risedronate (RIS) and raloxifene (RLX) on the response of bone to endogenous parathyroid hormone (PTH) induced by acute hypocalcemia."	5.14	Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. ( Stepan, JJ; Zikan, V, 2009)
"The results suggest that etidronate could prevent high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases."	5.11	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. ( Nakayamada, S; Okada, Y; Saito, K; Tanaka, Y, 2004)
"The FACT study (Fosamax Actonel Comparison Trial) was a 1-year-head-to-head trial comparing the efficacy and tolerability of once weekly (DW) alendronate 70 mg and OW risedronate 35 mg for the treatment of postmenopausal osteoporosis."	5.11	Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. ( Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE, 2004)
"The purpose of the present study was to compare the effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living (ADL) in elderly women with vertebral fractures."	5.10	Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. ( Ichimura, S; Iwamoto, J; Takeda, T; Uzawa, M, 2003)
" The parent compound, etidronate, was first used in multicentered trials for the treatment of primary osteoporosis and showed some success in increasing bone density and perhaps controlling fracture rates."	4.79	Bisphosphonate therapy. ( Licata, AA, 1997)
" aestivum (200 and 400 mg/kg/day, po, for 30 days) and risedronate (20 microg/kg, sc, five times a week for 30 days) following methyl prednisolone sodium succinate (10 mg/kg, sc, thrice a week for 4 weeks) induced osteoporosis in Wistar rats showed an increase in the serum levels of bone mineral content markers, decrease in the serum and urinary levels of bone resorption markers."	3.80	Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. ( Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL, 2014)
"The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)."	3.78	Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012)
"3-(3-Pyridyl)-2-hydroxy-2-phosphonopropanoic acid (3-PEHPC, 1) is a phosphonocarboxylate (PC) analogue of 2-(3-pyridyl)-1-hydroxyethylidenebis(phosphonic acid) (risedronic acid, 2), an osteoporosis drug that decreases bone resorption by inhibiting farnesyl pyrophosphate synthase (FPPS) in osteoclasts, preventing protein prenylation."	3.76	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. ( Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA, 2010)
"These results suggest that etidronate may 1) inhibit the entry of NBPs into cells related to inflammation and/or necrosis, 2) inhibit the binding of NBPs to bone hydroxyapatite, 3) at least partly eliminate (or substitute for) NBPs that have already accumulated within bones, and thus 4) if used as a substitution drug for NBPs, be effective at treating or preventing NBP-associated osteonecrosis of the jaw."	3.76	Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. ( Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M, 2010)
"Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin."	3.75	Etidronate disodium in the treatment of Paget's disease of bone. ( Krane, SM, 1982)
"This study was conducted to identify bone resorption and anti-inflammatory effects with intermittent cyclical etidronate therapy (ICET) in patients with rheumatoid arthritis, and anti-inflammatory effect of etidronate in vitro."	3.73	Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. ( Nagashima, M; Shue, G; Yamamoto, K; Yoshino, S, 2006)
"Transiliac bone biopsies carried out on 13 patients with Paget's disease to evaluate the effects of low-dose diphosphonate (disodium etidronate) therapy showed focal osteomalacia in the 9 patients in whom post-therapy specimens were taken through pagetic bone."	3.67	Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. ( Boyce, BF; Boyle, IT; Fogelman, I; Johnston, E; Ralston, S; Smith, L, 1984)
" Attempts to prevent disuse osteoporosis with both mechanical and biochemical means, including exercise, skeletal compression, increased hydrostatic pressure to the lower body, supplemental calcium and/or phosphorus, calcitonin, or etidronate were not successful."	3.67	Skeletal calcium homeostasis and countermeasures to prevent disuse osteoporosis. ( McDonald, J; Schneider, VS, 1984)
"Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia."	3.66	[Treatment of hypercalcemia of tumoral origin with two diphosphonates]. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1980)
"Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia."	3.66	Parenteral diphosphonates for treating malignant hypercalcemia. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1981)
" Two groups of patients with either low (osteoporosis), (n = 15) or high (Paget's disease, n = 6) bone turnover were studied before and after sodium fluoride (NaF) and diphosphonate (EHDP) treatment, respectively."	3.65	Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease. ( Dambacher, MA; Guncaga, J; Haas, HG; Lauffenburger, T; Lentner, C; Olah, AJ, 1977)
"Cows fed a balanced diet with the required amounts of calcium and phosphorus developed acute hypocalcemia and hypophosphatemia shortly after parturition, even in the presence of the a responsive parathyroid gland, when bone resorption was selectively inhibited by the prepartal administration of disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP)."	3.65	Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. ( Black, HE; Capen, CC; Geho, WB; Potts, JT; Re, R; Yarrington, JT, 1976)
"Secondary outcomes included changes in bone resorption (betaCTX) and 12-month changes in BMD."	2.75	Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. ( Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B, 2010)
" Despite serum isoflavone profiles indicating bioavailability of the phytoestrogens, only soy isoflavones from the cotyledon and germ significantly decreased net bone resorption by 9% (P = 0."	2.74	Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. ( Barnes, S; Boris, ME; Jackson, GS; Martin, BR; McCabe, GP; McCabe, LD; Nolan, JR; Peacock, M; Reinwald, S; Weaver, CM, 2009)
"Bisphosphonates decrease bone resorption and bone formation."	2.73	Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. ( Iizuka, T; Matsukawa, M, 2008)
"Proximal bone resorption around the femoral stem often has been observed after total hip arthroplasty (THA), could lead to late stem loosening."	2.73	Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. ( Fuji, T; Masuhara, K; Nakai, T; Seino, Y; Yamaguchi, K; Yamasaki, S, 2007)
"One of the most widely used bone resorption markers is cross-linked N-terminal telopeptides (NTX)."	2.73	Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. ( Abe, Y; Fukao, A; Ishikawa, H, 2008)
"The effect of risedronate treatment on bone resorption was investigated quantitatively by measuring N-telopeptide levels in urine of patients with hip fracture."	2.73	[The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. ( Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT, 2007)
"Urinary deoxypyridinoline, a bone resorption marker, decreased by 46."	2.73	Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. ( Honda, Y; Iwamoto, J; Sato, Y, 2007)
"There is no well-established treatment for osteoporosis in male patients with leprosy, because no clinical trials have examined the efficacy of treatment on bone mineral density (BMD) or fracture incidence in such patients."	2.72	Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. ( Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H, 2006)
"Etidronate was taken orally in a regimen repeated every 14 weeks, and periprosthetic BMD was measured with dual energy X-ray absorptiometry (DXA) in the total periprosthetic area and in the seven Gruen zones at 1 week (baseline), 6 weeks, 3 months, 6 months, and 12 months postoperatively."	2.72	Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. ( Fokter, SK; Komadina, R; Repse-Fokter, A, 2006)
"Risedronate does not suppress bone resorption deeply that enhances the bone recovers quickly after withdrawal."	2.71	Monitoring of Risedronate by biochemical bone markers in clinical practice. ( Bunyaratavej, N, 2005)
"Etidronate was effective at inhibiting bone resorption and destruction in study patients with RA, while not increasing BAP concentrations; and a correlation was observed between the concentration of DPD and IL-6, indicating the antiinflammatory effect of etidronate."	2.71	Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. ( Hasegawa, J; Katsumata, S; Nagashima, M; Nishijima, T; Yamamoto, M; Yoshino, S, 2003)
"Greater decreases in bone resorption markers were associated with greater decreases in vertebral (and nonvertebral) fractures."	2.71	Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. ( Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA, 2003)
"To compare the effects of alendronate (ALN) 70 mg once weekly (OW) and risedronate (RIS) 5 mg daily between-meal dosing on biochemical markers of bone turnover and bone mineral density (BMD) in postmenopausal women with osteoporosis."	2.71	Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. ( Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L, 2003)
"Etidronate therapy inhibits bone resorption and improves calcium balance, and such therapy may prevent bone loss and reduce the risk of subsequent hip fracture."	2.71	Beneficial effect of etidronate therapy in immobilized hip fracture patients. ( Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K; Yasuda, H, 2004)
"These preliminary data suggest that the addition of cyclic sodium etidronate in combination with low-dose norethindrone to GnRH agonists is an effective means of ameliorating the hypoestrogenic side effects induced by GnRH agonist alone."	2.67	Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. ( Fournet, N; Judd, HL; Surrey, ES; Voigt, B, 1993)
"Risedronate decreases strongly bone resorption and turnover via a potent inhibitory action on osteoclasts."	2.45	[Risedronate for treatment of osteoporosis]. ( Hagino, H, 2009)
" Alternative dosing schedules and routes of administration have become available and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such as osteoporosis."	2.43	Oral antiresorptive therapy. ( Hosking, DJ; Pande, I, 2005)
"Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts."	2.41	Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002)
" Oral dosing should not be substituted for intravenous administration in the treatment of malignant osteolysis."	2.41	Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000)
"It is an effective inhibitor of bone resorption, but unlike etidronate does not impair the mineralization of bone."	2.40	Clodronate. ( Kanis, JA; McCloskey, EV, 1997)
"The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate bone metastases at autopsy."	2.40	Bisphosphonates and breast carcinoma. ( Lipton, A, 1997)
"The amount of bone loss in algodystrophy in a few weeks or months is what might be expected over 10 years during the natural history of uncomplicated osteoporosis."	2.40	Further vascular, bone and autonomic investigations in algodystrophy. ( Audran, M; Baslé, MF; Bregeon, C; Legrand, E; Masson, C; Namour, A; Pascaretti, C; Renier, JC; Saumet, JL, 1998)
"Many of the bisphosphonates inhibit bone resorption, the newest compounds being 10,000 times more active than etidronate, the first bisphosphonate described."	2.40	Bisphosphonates: preclinical aspects and use in osteoporosis. ( Fleisch, HA, 1997)
" Mineralisation defects in forming bone may be avoided by the use of an initial dosage of 5 mg/kg/day for up to 6 months; dosages above 10 mg/kg/day should be limited to 3 months' duration, and dosages greater than 20 mg/kg/day should be avoided."	2.39	Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. ( Dunn, CJ; Fitton, A; Sorkin, EM, 1994)
"Osteoporosis is a common disorder affecting the health of many adults."	2.39	Treatment of osteoporosis. ( Pilbeam, CC; Prestwood, KM; Raisz, LG, 1995)
"Hip fractures have been neglected."	2.39	Present and future of osteoporosis therapy. ( Bass, S; Pearce, G; Seeman, E; Tsalamandris, C, 1995)
"Etidronate has specific site and bone cell actions in the periodontium."	1.38	The effect of etidronate on the periodontium of ovariectomized rats. ( Berdal, A; El Ayeb, H; Ghoul-Mazgar, S; Khemiss, F; Ruhin-Poncet, B; Said, F; Saidane, D, 2012)
"Untreated minipigs displayed a deep bone resorption pit, beneath the graft region, filled with type I collagen tissue as determined through immunohistochemical staining."	1.35	Effect of risedronate in a minipig cartilage defect model with allograft. ( Abe, Y; Li, J; Masuda, K; Muehleman, C; Pfister, B; Phipps, R; Sah, RL, 2009)
"We studied 1515 women with postmenopausal osteoporosis under treatment with anti-resorbing agents (alendronate, risedronate, raloxifene) for 13."	1.35	Vitamin D status and response to treatment in post-menopausal osteoporosis. ( Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L, 2009)
"Risedronate decreased bone cancer-related bone destruction and pain-related behavior and decreased the spinal expression of glial fibrillary acidic protein, whereas NE-10790 had no effect on these parameters."	1.35	Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. ( Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW, 2009)
" In two groups, anterior cruciate ligament transection was performed and half were left untreated, and the other half dosed with risedronate (0."	1.35	Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. ( Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF, 2008)
"Otosclerosis is a bony dyscrasia characterized by histopathological findings of osteoclast production."	1.35	Medical treatment of otosclerosis: rationale for use of bisphosphonates. ( Brookler, K, 2008)
"Osteoporosis is a severe complication of glucocorticoid treatment."	1.34	Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. ( Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S, 2007)
"The purposes of the present study were to differentiate the effects of pre-surgery treatment with risedronate and post-surgery treatment with a reduced dosing frequency of risedronate on trabecular bone loss in ovariectomized rats and to determine whether post-surgery treatment with a reduced dosing frequency of risedronate would have a beneficial effect on trabecular bone loss after pre-surgery treatment with risedronate by means of bone histomorphometric analysis."	1.33	Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. ( Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK, 2006)
"EHL of vesical calculi was again performed in April 2004."	1.33	Recurrent vesical calculi, hypercalciuria, and biochemical evidence of increased bone resorption in an adult male with paraplegia due to spinal cord injury: is there a role for intermittent oral disodium etidronate therapy for prevention of calcium phosph ( Buczynski, AZ; Fraser, WD; Grases, F; Heilberg, IP; Hughes, PL; Jonsson, O; Kohri, K; Schurch, B; Sett, P; Singh, G; Soni, BM; Tozawa, K; Vaidyanathan, S; Watson, ID; Wyndaele, JJ; Yasui, T, 2005)
"We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX."	1.33	Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006)
"Because on bone marker measurement bone resorption was increased and bone formation was decreased from baseline, treatment was switched to oral alendronate (5 mg/day, daily)."	1.31	Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. ( Iwamoto, J; Takeda, T, 2002)
" The purpose was to determine the effects of the anti-resorptive agents alone and in combination with intermittent PTH on bone formation in the mandible and a long bone in the aged ovariectomized (Ovx) rat."	1.31	Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. ( Hunziker, J; Miller, SC; Wronski, TJ, 2000)
" We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number."	1.31	Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. ( Halasy-Nagy, JM; Reszka, AA; Rodan, GA, 2001)
"Etidronate treatment (10 mg/kg per day subcutaneously) was initiated 2 weeks after surgery and was continued for 2 weeks."	1.31	Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. ( Ichimura, S; Iwamoto, J; Katsumata, T; Takeda, T; Tanaka, T; Toyama, Y, 2002)
"When the inhibition of bone resorption by calcitonin, osteoprotegerin, or alendronate is combined with the acute inhibition of bone mineralization with etidronate, the BRC model correctly predicts that there will no longer be a sharp rise in calcium and phosphate, and, therefore, there will no longer be the formation of the fetuin-mineral complex."	1.31	Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. ( Caputo, JM; Price, PA; Williamson, MK, 2002)
"These data suggest that the anti-bone resorption activities of TRK-530 are possibly unrelated to its antioxidant properties."	1.30	TRK-530 inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts. ( Funaba, Y; Kawabe, N; Nakadate-Matsushita, T; Tanahashi, M; Tateishi, A, 1998)
"With respect to markers of bone resorption, urinary deoxypyridinoline fell by 51% +/- 9% in group A patients and increased by 65% +/- 22% in group B patients by 3 months after transplantation (P < ."	1.30	Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. ( Addesso, V; Lo, SH; Mancini, D; McMahon, DJ; Michler, RE; Rodino, MA; Seibel, MJ; Shane, E; Staron, RB, 1998)
"Wear particle induced bone resorption is thought to be one of the mechanisms that contribute to implant loosening."	1.30	Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. ( Athanasou, NA; Fujikawa, Y; Murray, DW; Sabokbar, A, 1998)
"Human breast cancer frequently metastasizes to the skeleton to cause osteolysis and subsequent pain, pathological fracture, and hypercalcemia."	1.29	Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. ( Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T, 1995)
"In summary, increased bone resorption occurs after OLT with persistent decreased bone formation, leading to vertebral fracture in 25% of patients."	1.29	Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. ( Drent, G; Groen, EW; Haagsma, EB; Meerman, L; Oostdijk, A; Piers, DA; Riemens, SC; Slooff, MJ; Thijn, CJ; van Doormaal, JJ, 1996)
"The diagnostic criterion for postmenopausal osteoporosis was a bone mineral density (BMD) (Hologic QDR-1000) in lumbar spine and/or femoral neck more than 2 SD below the mean value corresponding to an age- and sex-matched healthy control group."	1.29	New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. ( de la Piedra, C; Diaz Diego, EM; Diaz Martin, MA; Disla, T; Guerrero, R; Rapado, A, 1996)
" L-T4 treatment resulted in reduction in BMDs in the lumbar spine, tail, and femur as measured by dual energy X-ray absorptiometry, but there was no correlation with the dosage of L-T4 or the serum T4 level."	1.29	A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression. ( Kung, AW; Ng, F, 1994)
"It is attributed to an increase in bone resorption and diminished bone formation characterized clinically by elevated serum calcium levels, hypercalciuria, increased risk of urinary lithiasis, and renal failure."	1.29	Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. ( Cross, LL; Meythaler, JM; Tuel, SM, 1993)
"Alendronate is an aminobisphosphonate that acts as a potent inhibitor of osteoclastic bone resorption."	1.29	Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. ( Azuma, Y; Kiyoki, M; Ohta, T; Okabe, K; Oue, Y; Sato, H; Tsuchimoto, M, 1995)
"It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroidectomized rats at a SC dose as low as 0."	1.28	BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. ( Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K, 1991)
"These data demonstrate that products of bone resorption, known to be chemotactic for mononuclear cells, stimulate PBMC IL-1 activity."	1.28	Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells. ( Avioli, LV; Carano, A; Jeffrey, JJ; Malone, JD; McCracken, R; Pacifici, R; Rifas, L; Santoro, SA, 1991)
"Significant inhibition of bone resorption in each case is seen only after 24-72 h of treatment."	1.28	Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. ( Blair, HC; Carano, A; Konsek, JD; Schlesinger, PH; Teitelbaum, SL, 1990)
"Osteoclastic bone resorption is activated by 7 days of oral neutral phosphate and inhibited with a brief pulse (5 days) of etidronate disodium at a high dose (20 mg/kg body weight)."	1.28	Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. ( LeBlanc, AD; Mallette, LE; Mechanick, JI; Pool, JL, 1989)
"Acute osteoporosis is known to occur after immobilization in spinal cord injured patients and is related to an early increase in osteoclastic bone resorption."	1.28	Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. ( Alexandre, C; Chappard, D; Minaire, P; Morukov, BV; Palle, S; Riffat, G; Rodionova, SS; Vico, L, 1989)
"The rat adjuvant arthritis model, like human rheumatoid arthritis, is characterized by fulminating intra- and periarticular inflammation and bone lysis."	1.28	NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. ( Boyce, RW; Francis, MD; Hovancik, K, 1989)
"Almost complete inhibition of bone resorption and bone mineralization occurred by 14 days of treatment without effects on skeletal collagen mass."	1.27	Effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) upon the kinetics of bone resorption and bone formation at the whole bone level in prelabelled chicks. ( Klein, L; Wong, KM, 1983)
"Exercise stimulated bone resorption and diphosphonate inhibited the osteoclastic activity."	1.27	Effects of a 120 day period of bed-rest on bone mass and bone cell activities in man: attempts at countermeasure. ( Alexandre, C; Chappard, D; Minaire, P; Morukov, B; Palle, S; Rakhmanov, S; Riffat, G; Vico, L, 1987)
"Osteolysis is estimated by the amount of 45Ca released from bone to medium, the mice being given injections of 45Ca on their day of birth."	1.26	Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. ( Barras, C; Baud, M; Courvoisier, B; Jung, A; Mermillod, B, 1981)
" In one group of animals, EHDP treatment was discontinued after one year of dosage at 5 mg/kg/day given subcutaneously."	1.26	The long-term skeletal effects of EHDP in dogs. ( Bevan, JA; Cloyd, GG; Flora, L; Hassing, GS; Parfitt, AM; Villanueva, AR, 1981)
" Ultrastructural studies on osteoclasts from EHDP-treated rats showed a general decrease in their vacuolization and amount of organelles as dosage of EHDP increased."	1.25	Ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Effects on growth and modeling of the rat tibia. ( Jee, WS; Miller, SC, 1975)

Research

Studies (232)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change in Bone Mineral Density (BMD) at the Spine (L1-L4) Based on Randomization to Control, Risedronate, or Exercise Group.

Timeframe	Studies, this research(%)	All Research%
pre-1990	56 (24.14)	18.7374
1990's	73 (31.47)	18.2507
2000's	83 (35.78)	29.6817
2010's	20 (8.62)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Szabo, CM	1
Martin, MB	1
Oldfield, E	1
Ishida, K	1
Ashizawa, N	1
Matsumoto, K	1
Kobashi, S	1
Kurita, N	1
Shigematsu, T	1
Iwanaga, T	1
Thomsen, JS	3
Straarup, TS	1
Danielsen, CC	2
Oxlund, H	2
Brüel, A	1
Matheny, JB	1
Slyfield, CR	1
Tkachenko, EV	1
Lin, I	1
Ehlert, KM	1
Tomlinson, RE	1
Wilson, DL	1
Hernandez, CJ	1
Okada, S	1
Kiyama, T	1
Sato, E	1
Tanaka, Y	4
Oizumi, T	2
Kuroishi, T	2
Takahashi, T	1
Sasaki, K	2
Sugawara, S	3
Endo, Y	3
Kikuta, J	1
Ishii, M	1
Banji, D	1
Banji, OJ	1
Chiluka, VL	1
Abbagoni, S	1
Iwamoto, J	11
Matsumoto, H	1
Takeda, T	9
Sato, Y	7
Liu, X	1
Yeh, JK	5
Adami, S	3
Giannini, S	2
Bianchi, G	1
Sinigaglia, L	1
Di Munno, O	1
Fiore, CE	1
Minisola, S	1
Rossini, M	1
Iizuka, T	1
Matsukawa, M	1
Muehleman, C	1
Li, J	2
Abe, Y	2
Pfister, B	1
Sah, RL	1
Phipps, R	1
Masuda, K	1
Lomashvili, KA	1
Monier-Faugere, MC	1
Wang, X	2
Malluche, HH	1
O'Neill, WC	1
Zikan, V	1
Stepan, JJ	1
Brookler, K	1
Izumi, K	1
Mizokami, A	1
Sugimoto, K	1
Narimoto, K	1
Miwa, S	1
Maeda, Y	1
Kadono, Y	2
Takashima, M	1
Koh, E	1
Namiki, M	1
Hagino, H	1
Hald, A	1
Hansen, RR	1
Thomsen, MW	1
Ding, M	1
Croucher, PI	1
Gallagher, O	1
Ebetino, FH	5
Kassem, M	1
Heegaard, AM	1
Kwak, HB	1
Kim, JY	1
Kim, KJ	1
Choi, MK	1
Kim, JJ	1
Kim, KM	1
Shin, YI	1
Lee, MS	1
Kim, HS	1
Kim, JW	1
Chun, CH	1
Cho, HJ	1
Hong, GY	1
Juhng, SK	1
Yoon, KH	1
Park, BH	1
Bae, JM	1
Han, JK	1
Oh, J	1
Weaver, CM	1
Martin, BR	1
Jackson, GS	1
McCabe, GP	1
Nolan, JR	1
McCabe, LD	1
Barnes, S	1
Reinwald, S	1
Boris, ME	1
Peacock, M	1
Keel, C	1
Kraenzlin, ME	1
Kraenzlin, CA	1
Müller, B	1
Meier, C	1
Allen, MR	1
Erickson, AM	1
Burr, DB	2
Martin, RB	1
Hazelwood, SJ	1
Ohtori, S	1
Akazawa, T	1
Murata, Y	1
Kinoshita, T	1
Yamashita, M	1
Nakagawa, K	1
Inoue, G	1
Nakamura, J	1
Orita, S	1
Ochiai, N	1
Kishida, S	1
Takaso, M	1
Eguchi, Y	1
Yamauchi, K	1
Suzuki, M	1
Aoki, Y	1
Takahashi, K	1
Funayama, H	2
Yamaguchi, K	2
Yokoyama, M	1
Takahashi, H	1
Yamamoto, M	2
Kumamoto, H	1
Kawamura, H	1
McKenna, CE	1
Kashemirov, BA	1
Błazewska, KM	1
Mallard-Favier, I	1
Stewart, CA	1
Rojas, J	1
Lundy, MW	1
Baron, RA	1
Dunford, JE	1
Kirsten, ML	1
Seabra, MC	1
Bala, JL	1
Marma, MS	1
Rogers, MJ	4
Coxon, FP	3
Aspenberg, P	1
Schilcher, J	1
Fahlgren, A	1
Fournier, PG	1
Stresing, V	1
Clézardin, P	1
Heidari, P	1
Abbaspour, A	1
Baghdadi, T	1
Espandar, R	1
Farzan, M	1
Amanpour, S	1
Rasouli, MR	1
Mohagheghi, MA	1
Amiri, HR	1
Yasui, N	1
Winzenberg, T	1
Jones, G	1
Miller, KK	1
Meenaghan, E	1
Lawson, EA	1
Misra, M	1
Gleysteen, S	1
Schoenfeld, D	1
Herzog, D	1
Klibanski, A	1
Matsumoto, T	1
Nagase, Y	1
Iwasawa, M	1
Yasui, T	2
Masuda, H	1
Nakamura, K	1
Tanaka, S	2
Sköldenberg, OG	1
Salemyr, MO	1
Bodén, HS	1
Ahl, TE	1
Adolphson, PY	1
Sergi, G	1
Pintore, G	1
Falci, C	1
Veronese, N	1
Berton, L	1
Perissinotto, E	1
Basso, U	1
Brunello, A	1
Monfardini, S	1
Manzato, E	1
Coin, A	1
Said, F	1
Ghoul-Mazgar, S	1
Khemiss, F	1
El Ayeb, H	1
Saidane, D	1
Berdal, A	1
Ruhin-Poncet, B	1
Kamizono, J	1
Okada, Y	2
Shirahata, A	1
Eriksen, EF	3
Melsen, F	2
Sod, E	1
Barton, I	3
Chines, A	2
Berenson, JR	2
Hasegawa, J	1
Nagashima, M	2
Nishijima, T	1
Katsumata, S	1
Yoshino, S	2
Takami, M	1
Suda, K	1
Sahara, T	1
Itoh, K	1
Nagai, K	1
Sasaki, T	2
Udagawa, N	3
Takahashi, N	3
Shao, P	1
Ohtsuka-Isoya, M	1
Shinoda, H	2
Eastell, R	3
Hannon, RA	2
Garnero, P	3
Delmas, PD	3
Ichimura, S	3
Matsu, K	1
Uzawa, M	2
Hosking, D	2
Felsenberg, D	1
Andia, JC	1
Välimäki, M	1
Benhamou, L	1
Reginster, JY	2
Yacik, C	1
Rybak-Feglin, A	1
Petruschke, RA	1
Zaru, L	1
Santora, AC	1
Nakamura, M	1
Matsuura, S	1
Mogi, M	1
Nakamura, H	1
Horiuchi, H	1
Saito, N	1
Hiraoka, BY	1
Kobayashi, Y	1
Takaoka, K	1
Ozawa, H	1
Miyazawa, H	1
Nakayamada, S	1
Saito, K	1
Callaci, JJ	1
Juknelis, D	1
Patwardhan, A	1
Sartori, M	1
Frost, N	1
Wezeman, FH	1
Seibel, MJ	2
Naganathan, V	1
Grauer, A	1
Harada, H	1
Nakayama, T	1
Nanaka, T	1
Katsumata, T	2
Kanoko, T	1
Yasuda, H	1
Satoh, K	1
Kishimoto, H	1
Shiraki, M	1
Li, CY	1
Price, C	1
Delisser, K	1
Nasser, P	1
Laudier, D	1
Clement, M	1
Jepsen, KJ	1
Schaffler, MB	1
Vaidyanathan, S	1
Watson, ID	1
Jonsson, O	1
Buczynski, AZ	1
Grases, F	1
Heilberg, IP	1
Wyndaele, JJ	1
Tozawa, K	1
Kohri, K	1
Schurch, B	1
Hughes, PL	1
Singh, G	1
Soni, BM	1
Sett, P	1
Fraser, WD	2
Sebba, AI	1
Bonnick, SL	1
Kagan, R	1
Thompson, DE	1
Skalky, CS	1
Chen, E	1
de Papp, AE	1
Pande, I	1
Hosking, DJ	3
Ohsako, M	1
Monma, Y	1
Mayanagi, H	1
Reszka, AA	3
Rodan, GA	3
Maricic, M	1
Rackoff, PJ	1
Sebba, A	1
Suzuki, K	1
Takeyama, S	1
Kikuchi, T	1
Yamada, S	1
Sodek, J	1
Yamamoto, K	1
Shue, G	1
Heaney, RP	1
Valent, DJ	1
Barton, IP	1
Takada, J	1
Seki, A	3
Yamada, H	4
Shen, CL	3
Hamano, T	2
Fujii, N	2
Nagasawa, Y	2
Isaka, Y	2
Moriyama, T	2
Okada, N	1
Imai, E	2
Horio, M	2
Ito, T	2
Iwata, K	1
Follet, H	1
Phipps, RJ	1
Fokter, SK	1
Komadina, R	1
Repse-Fokter, A	1
Kanaji, A	1
Higashi, M	1
Namisato, M	1
Nishio, M	1
Ando, K	1
Mikami, S	1
Hori, M	1
Honda, Y	1
Altintaş, F	1
Ozkut, AT	1
Beyzadeoğlu, T	1
Eren, A	1
Güven, M	1
Bunyaratavej, N	1
Yamasaki, S	1
Masuhara, K	1
Nakai, T	1
Fuji, T	1
Seino, Y	1
Campbell, MJ	1
Aronstein, WS	1
Cohen, SB	1
Conaghan, PG	1
Cline, GA	1
Christiansen, C	1
Beary, JF	1
Meyer, JM	1
Bingham, CO	1
Dalle Carbonare, L	1
Bertoldo, F	1
Valenti, MT	1
Zordan, S	1
Sella, S	1
Fassina, A	1
Turco, G	1
Realdi, G	1
Lo Cascio, V	1
Suzuki, Y	1
Nishiyama, T	1
Hasuda, K	1
Fujishiro, T	1
Niikura, T	1
Hayashi, S	1
Hashimoto, S	1
Kurosaka, M	1
MacNeil, JA	1
Doschak, MR	1
Zernicke, RF	1
Boyd, SK	1
Cesareo, R	1
Iozzino, M	1
Alva, D	1
Napolitano, C	1
De Rosa, B	1
Contini, S	1
Mallardo, L	1
Lauria, A	1
Reda, G	1
Orsini, A	1
Ishikawa, H	1
Fukao, A	1
Thompson, K	1
Roelofs, AJ	1
Dane, C	1
Dane, B	1
Cetin, A	1
Erginbas, M	1
Boyce, BF	2
Smith, L	1
Fogelman, I	1
Johnston, E	1
Ralston, S	1
Boyle, IT	2
Nuti, R	1
Righi, G	1
Turchetti, V	1
Vattimo, A	1
Jung, A	4
Bornand, J	1
Mermillod, B	2
Edouard, C	3
Meunier, PJ	3
Krane, SM	1
Fleisch, H	5
Klein, L	2
Wong, KM	1
Rondier, J	1
Huchet, B	1
Cayla, J	1
Schneider, VS	1
McDonald, J	1
Raisz, LG	2
Barras, C	1
Baud, M	1
Courvoisier, B	3
van Ouwenaller, C	2
Chantraine, A	2
Flora, L	2
Hassing, GS	1
Cloyd, GG	1
Bevan, JA	2
Parfitt, AM	1
Villanueva, AR	1
Alexandre, C	4
Khairi, RA	1
Johnston, CC	1
Zucchelli, P	1
Catizone, L	1
Casanova, S	1
Fabbri, L	1
Fusaroli, M	1
Jee, WS	6
Lin, BY	1
Ma, YF	1
Ke, HZ	3
Blumsohn, A	1
Naylor, KE	1
Assiri, AM	1
Prestwood, KM	1
Pilbeam, CC	1
Sasaki, A	1
Story, B	1
Wright, KR	1
Chapman, M	1
Boyce, R	1
Mundy, GR	2
Yoneda, T	1
Li, M	1
Mosekilde, L	3
Søgaard, CH	2
Wronski, TJ	6
Haddad, JG	1
Boyce, RW	4

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology[NCT02367846]	Phase 4	6 participants (Actual)	Interventional	2015-01-31	Active, not recruiting
Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover[NCT02630797]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2017-01-12	Active, not recruiting
A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis[NCT00092014]	Phase 3	1,053 participants (Actual)	Interventional	2002-09-01	Completed
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600]	Phase 3	276 participants (Actual)	Interventional	2015-02-01	Completed
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420]	Phase 1	4 participants (Actual)	Interventional	2005-12-31	Completed
Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203]	Phase 2	120 participants (Actual)	Interventional	2002-10-31	Completed
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial[NCT01400516]	Phase 4	26 participants (Actual)	Interventional	2011-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months

Change in Bone Strength Index of the Distal Tibia Based on Randomization to Control, Risedronate, or Exercise Group.

Intervention	g/cm^2 (Mean)
	Baseline	6 Months	12 Months
Control	0.889	.887	0.885
Exercise	0.886	.878	0.885
Risedronate	0.892	.907	0.911

"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months

Change in Serum Measures of Bone Resorption (Serum NTx) Based on Randomization to Control, Risedronate, or Exercise Group.

Intervention	mg^2/mm^4 (Mean)
	Baseline	6 Months	12 Months
Control	2098.7	2105.89	2107.2
Exercise	2001	1987.42	2009.2
Risedronate	1993.3	1997.32	2014.2

Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months

Change From Baseline in Bone Mineral Density (BMD) Measured by Dual-Energy X-ray Absorptiometry (DXA) and Instant Vertebral Assessment (IVA) Scan

Intervention	nanoMolar Bone Collagen Equivalents/L (Mean)
	Baseline	6 Months	12 Months
Control	13.99	12.16	12.36
Exercise	15.03	13.36	13.92
Risedronate	14.31	10.30	11.42

BMD was measured at the lumbosacral spine antero-posterior and at the femoral neck using a densitometer. A positive change from Baseline (increased bone density) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Disease Activity Score 28 Joint Count C-Reactive Protein (DAS-28 CRP)

Intervention	grams/centimeters squared (g/cm^2) (Mean)
	Spine, Baseline	Spine, Change from Baseline at Month12	Femoral neck, Baseline	Femoral neck, Change from Baseline at Month 12
Control Arm	0.93	-0.002	0.73	-0.03
Teriparatide	0.91	0.06	0.68	0.03

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and C-Reactive Protein (CRP) for a total possible score of 2 to 10. Higher values indicate higher disease activity. A negative change from baseline indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Change From Baseline in Joint Erosion Volume Measured by 3-Dimensional Computed Tomography (3D CT) Scan

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 12
Control Arm	2.73	-0.50
Teriparatide	2.66	0.42

Both hands were scanned using a CT scanner. A semi-automated software tool was used to segment the erosion margins in 3D. A board certified radiologist identified the individual erosions in six sub-regions: radius, ulna, proximal carpals, distal carpals, metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints. The average total in a single hand/wrist was calculated. A negative change from Baseline(less joint erosions) indicates improvement. (NCT01400516)
Timeframe: Baseline and Month 12

Article	Year
[Dynamics of bone resorption analyzed by intravital imaging]. Clinical calcium, 2013, Volume: 23, Issue:11 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal;	2013
[Risedronate for treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:5 Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spont	2009
Treatment of hypercalcemia of malignancy with bisphosphonates. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 21 Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H	2002
[Risedronate treatment for osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fra	2004
[Concurrent treatment of osteoporosis with bisphosphonate and vitamin K2]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Animals; Bone Density; Bone Resorption; Drug Therapy, Combination; Etidronic Acid; Humans; Osteoporo	2004
Oral antiresorptive therapy. Current rheumatology reports, 2005, Volume: 7, Issue:1 Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, C	2005
Mechanism of action of bisphosphonates. Current osteoporosis reports, 2003, Volume: 1, Issue:2 Topics: Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteoporosis; Sensitivity a	2003
Glucocorticoid-induced osteoporosis: treatment options and guidelines. Current osteoporosis reports, 2005, Volume: 3, Issue:1 Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractu	2005
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Treatments in endocrinology, 2005, Volume: 4, Issue:4 Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans;	2005
Pharmacological therapy of Paget's and other metabolic bone diseases. Bone, 2006, Volume: 38, Issue:2 Suppl 2 Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidron	2006
[Application of anti-resorptive drugs for the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64, Issue:2 Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans;	2006
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures. Minerva endocrinologica, 2007, Volume: 32, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosph	2007
Etidronate disodium in the treatment of Paget's disease of bone. Annals of internal medicine, 1982, Volume: 96, Issue:5 Topics: Bone Resorption; Calcitonin; Clinical Trials as Topic; Diphosphates; Drug Evaluation; Etidronic Acid	1982
Diphosphonates: history and mechanisms of action. Metabolic bone disease & related research, 1981, Volume: 3, Issue:4-5 Topics: Animals; Bone Resorption; Calcification, Physiologic; Calcinosis; Calcium Phosphates; Clodronic Acid	1981
Treatment of osteoporosis. Annual review of medicine, 1995, Volume: 46 Topics: Adult; Aged; Bone Resorption; Calcitonin; Calcium, Dietary; Combined Modality Therapy; Estrogen Repl	1995
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs & aging, 1994, Volume: 5, Issue:6 Topics: Bone Diseases; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Drug Administration Sched	1994
Primary osteoporosis. Methods to combat bone loss that accompanies aging. Postgraduate medicine, 1993, Volume: 93, Issue:8 Topics: Adult; Age Factors; Aged; Bone Density; Bone Remodeling; Bone Resorption; Calcitonin; Calcium; Causa	1993
Present and future of osteoporosis therapy. Bone, 1995, Volume: 17, Issue:2 Suppl Topics: Bone Density; Bone Development; Bone Resorption; Calcitonin; Calcitriol; Calcium, Dietary; Diphospho	1995
Bisphosphonate therapy. The American journal of the medical sciences, 1997, Volume: 313, Issue:1 Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid;	1997
Use of bisphosphonates in cancer patients. Cancer treatment reviews, 1996, Volume: 22, Issue:4 Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid	1996
Bisphosphonates: preclinical aspects and use in osteoporosis. Annals of medicine, 1997, Volume: 29, Issue:1 Topics: Alendronate; Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteo	1997
Bisphosphonates and breast carcinoma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic	1997
Bisphosphonates in multiple myeloma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye	1997
Bisphosphonates in prostate carcinoma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C	1997
Clodronate. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Diseases; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Etidronic Acid; Female; Hum	1997
Further vascular, bone and autonomic investigations in algodystrophy. Acta orthopaedica Belgica, 1998, Volume: 64, Issue:1 Topics: Absorptiometry, Photon; Autonomic Nervous System; Autonomic Nervous System Diseases; Blood Vessels;	1998
Risedronate. Drugs & aging, 1998, Volume: 13, Issue:1 Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resor	1998
Aredia: the once-monthly infusion for the treatment of bone metastases. Current opinion in oncology, 1998, Volume: 10 Suppl 1 Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic;	1998
Prediction and assessment of the response of Paget's disease to bisphosphonate treatment. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Etidronic Acid; Half-Life; Humans; Osteitis D	1999
The use of risedronate in Paget's disease. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia,	1999
Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer, 2000, Jan-01, Volume: 88, Issue:1 Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm	2000
Risedronate: clinical usage. International journal of clinical practice, 2001, Volume: 55, Issue:4 Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Ostei	2001
Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects. Clinical orthopaedics and related research, 1975, Issue:108 Topics: Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcinosis; Calcium; Calcium M	1975
Bone metastases and tumor-induced hypercalcemia. Current opinion in oncology, 1992, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho	1992
New treatments for osteoporosis. Lancet (London, England), 1990, May-05, Volume: 335, Issue:8697 Topics: Bone Density; Bone Development; Bone Resorption; Drug Administration Schedule; Etidronic Acid; Femal	1990
Bone metastases and breast cancer. Cancer treatment reviews, 1985, Volume: 12, Issue:4 Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin	1985
Effects of clodronate on immobilization bone loss. Bone, 1987, Volume: 8 Suppl 1 Topics: Animals; Bone and Bones; Bone Resorption; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidr	1987
Dynamic radiologic patterns of Paget's disease of bone. Clinical orthopaedics and related research, 1987, Issue:217 Topics: Biomechanical Phenomena; Bone and Bones; Bone Development; Bone Resorption; Calcitonin; Diphosphonat	1987

Article	Year
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients. Climacteric : the journal of the International Menopause Society, 2008, Volume: 11, Issue:4 Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bo	2008
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone. Bone, 2009, Volume: 44, Issue:4 Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10 Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radi	2009
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:1 Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents;	2010
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2010, Volume: 17, Issue:2 Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation	2010
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:7 Topics: Administration, Cutaneous; Adult; Androgens; Anorexia Nervosa; Bone Density; Bone Density Conservati	2011
The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial. The Journal of bone and joint surgery. American volume, 2011, Oct-19, Volume: 93, Issue:20 Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Analysis of Variance; Arthroplasty, Repla	2011
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone, 2002, Volume: 31, Issue:5 Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Ag	2002
Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. The Journal of rheumatology, 2003, Volume: 30, Issue:3 Topics: Aged; Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Densi	2003
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2003, Volume: 18, Issue:6 Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Ac	2003
Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2003, Volume: 8, Issue:4 Topics: Aged; Aged, 80 and over; Bone Density; Bone Resorption; Drug Therapy, Combination; Etidronic Acid; F	2003
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Current medical research and opinion, 2003, Volume: 19, Issue:5 Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium C	2003
Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. The Journal of rheumatology, 2004, Volume: 31, Issue:1 Topics: Adjuvants, Immunologic; Adult; Autoimmune Diseases; Bone Density; Bone Resorption; Drug Therapy, Com	2004
Comparative effects of treatment with etidronate and alendronate on bone resorption, back pain, and activities of daily living in elderly women with vertebral fractures. The Keio journal of medicine, 2003, Volume: 52, Issue:4 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alendronate; Back Pain; Bone Resorption; Disabi	2003
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2004, Volume: 19, Issue:2 Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteopo	2004
Beneficial effect of etidronate therapy in immobilized hip fracture patients. American journal of physical medicine & rehabilitation, 2004, Volume: 83, Issue:4 Topics: Aged; Bone and Bones; Bone Resorption; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid;	2004
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Current medical research and opinion, 2004, Volume: 20, Issue:12 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Do	2004
Effect of etidronate in preventing periprosthetic bone loss following cemented hip arthroplasty: a randomized, double blind, controlled trial. Wiener klinische Wochenschrift, 2006, Volume: 118 Suppl 2 Topics: Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Resorption; Cementation	2006
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. Leprosy review, 2006, Volume: 77, Issue:2 Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Bli	2006
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6 Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination	2007
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology, 2007, Mar-20, Volume: 68, Issue:12 Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bo	2007
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. Acta orthopaedica et traumatologica turcica, 2007, Volume: 41, Issue:2 Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collage	2007
Monitoring of Risedronate by biochemical bone markers in clinical practice. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:suppl 5 Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bo	2005
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2007, Volume: 18, Issue:7 Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bo	2007
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis and cartilage, 2008, Volume: 16, Issue:6 Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Collagen	2008
Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. The Tohoku journal of experimental medicine, 2008, Volume: 214, Issue:1 Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Meth	2008
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2008, Volume: 24, Issue:4 Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resor	2008
Etidronate disodium in the treatment of Paget's disease of bone. Annals of internal medicine, 1982, Volume: 96, Issue:5 Topics: Bone Resorption; Calcitonin; Clinical Trials as Topic; Diphosphates; Drug Evaluation; Etidronic Acid	1982
Antiresorptive drugs and trabecular bone turnover: validation and testing of a computer model. Calcified tissue international, 1994, Volume: 54, Issue:3 Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Bone Development; Bone Remodeling; Bone Resorp	1994
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1993, Volume: 8, Issue:2 Topics: Aged; Bone Density; Bone Remodeling; Bone Resorption; Double-Blind Method; Etidronic Acid; Female; H	1993
Effects of sodium etidronate in combination with low-dose norethindrone in patients administered a long-acting GnRH agonist: a preliminary report. Obstetrics and gynecology, 1993, Volume: 81, Issue:4 Topics: Bone Density; Bone Resorption; Drug Therapy, Combination; Endometriosis; Estrogens; Etidronic Acid;	1993
Cyclical etidronate: its effect on bone density in patients with acute spinal cord injury. Archives of physical medicine and rehabilitation, 1997, Volume: 78, Issue:3 Topics: Acute Disease; Adult; Bone Density; Bone Resorption; Drug Administration Schedule; Etidronic Acid; F	1997
Bisphosphonates in multiple myeloma. Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye	1997
Treatment of Paget's disease of bone with alendronate. Bone, 1999, Volume: 24, Issue:5 Suppl Topics: Adult; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Bone Resorption; Etidronic Acid;	1999
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis and rheumatism, 1999, Volume: 42, Issue:11 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarker	1999
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcified tissue international, 2002, Volume: 71, Issue:2 Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dos	2002
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. The New England journal of medicine, 1990, May-03, Volume: 322, Issue:18 Topics: Administration, Oral; Aged; Bone and Bones; Bone Resorption; Double-Blind Method; Drug Administratio	1990
Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet (London, England), 1989, Nov-18, Volume: 2, Issue:8673 Topics: Administration, Oral; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration	1989
Effects of clodronate on immobilization bone loss. Bone, 1987, Volume: 8 Suppl 1 Topics: Animals; Bone and Bones; Bone Resorption; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidr	1987
Diphosphonates in Paget's disease. Lancet (London, England), 1974, May-11, Volume: 1, Issue:7863 Topics: Administration, Oral; Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Resorption; Calcium; Clinic	1974

Article	Year
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14 Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphos	2002
Novel bisphosphonate compound FYB-931 preferentially inhibits aortic calcification in vitamin D3-treated rats. Journal of bone and mineral metabolism, 2019, Volume: 37, Issue:5 Topics: Animals; Aorta; Biomarkers; Bone Resorption; Cells, Cultured; Cholecalciferol; Diphosphonates; Etidr	2019
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis. Scandinavian journal of rheumatology, 2013, Volume: 42, Issue:5 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, A	2013
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study. Bone, 2013, Volume: 57, Issue:1 Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Etidronic Acid; Female;	2013
Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice. The Tohoku journal of experimental medicine, 2013, Volume: 231, Issue:2 Topics: Animals; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Foscarnet; Imidazo	2013
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats. Indian journal of experimental biology, 2014, Volume: 52, Issue:2 Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Gl	2014
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats. Calcified tissue international, 2008, Volume: 83, Issue:2 Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Dru	2008
Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009, Volume: 20, Issue:2 Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation A	2009
Effect of risedronate in a minipig cartilage defect model with allograft. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2009, Volume: 27, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Chondrocytes; Coll	2009
Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney international, 2009, Volume: 75, Issue:6 Topics: Animals; Aortic Diseases; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcinosis; D	2009
Medical treatment of otosclerosis: rationale for use of bisphosphonates. The international tinnitus journal, 2008, Volume: 14, Issue:2 Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined	2008
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology, 2009, Volume: 73, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Resorption; Et	2009
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790. International journal of cancer, 2009, Sep-01, Volume: 125, Issue:5 Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone	2009
Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:7 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Cell Su	2009
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcified tissue international, 2010, Volume: 86, Issue:1 Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggreg	2010
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, Extern	2010
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Surv	2010
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack. Acta orthopaedica, 2010, Volume: 81, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female;	2010
How do bisphosphonates inhibit bone metastasis in vivo? Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7 Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell L	2010
Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model. Journal of orthopaedic surgery (Hong Kong), 2010, Volume: 18, Issue:2 Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Disease Models, Anima	2010
When do bisphosphonates make the most sense? The Journal of family practice, 2011, Volume: 60, Issue:1 Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Re	2011
Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis. Arthritis and rheumatism, 2011, Volume: 63, Issue:12 Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density; Bone Density	2011
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. Journal of bone and mineral metabolism, 2012, Volume: 30, Issue:4 Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De	2012
The effect of etidronate on the periodontium of ovariectomized rats. Journal of periodontology, 2012, Volume: 83, Issue:8 Topics: Acid Phosphatase; Alveolar Process; Animals; Biomarkers; Bone Density Conservation Agents; Bone Matr	2012
Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:11 Topics: Bone Resorption; Diphosphonates; Etidronic Acid; Female; Histiocytosis, Langerhans-Cell; Humans; Inf	2002
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2002, Volume: 7, Issue:6 Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Dose-Response Relationship,	2002
Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts. Bone, 2003, Volume: 32, Issue:4 Topics: Actins; Animals; Bone Resorption; Cells, Cultured; Diphosphonates; Enzyme Inhibitors; Etidronic Acid	2003
Circadian rhythms in serum bone markers and their relation to the effect of etidronate in rats. Chronobiology international, 2003, Volume: 20, Issue:2 Topics: Acid Phosphatase; Alkaline Phosphatase; Amino Acids; Animals; Biomarkers; Bone and Bones; Bone Densi	2003
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. Endocrinology, 2003, Volume: 144, Issue:12 Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption;	2003
The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment. Alcoholism, clinical and experimental research, 2004, Volume: 28, Issue:1 Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Diphosphonates; Ethano	2004
Effects of bisphosphonates on joint damage and bone loss in rat adjuvant-induced arthritis. Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2004, Volume: 53, Issue:2 Topics: Alendronate; Animals; Arthritis, Experimental; Bone Density; Bone Resorption; Diphosphonates; Etidro	2004
Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005, Volume: 20, Issue:1 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Diphosphonates; Dogs; Drug Resistance; Etidronic	2005
Recurrent vesical calculi, hypercalciuria, and biochemical evidence of increased bone resorption in an adult male with paraplegia due to spinal cord injury: is there a role for intermittent oral disodium etidronate therapy for prevention of calcium phosph Spinal cord, 2005, Volume: 43, Issue:5 Topics: Adult; Bone Resorption; Calcium; Etidronic Acid; Follow-Up Studies; Humans; International Cooperatio	2005
Inhibition of inflammatory and bone-resorption-inhibitory effects of alendronate by etidronate. Calcified tissue international, 2005, Volume: 76, Issue:6 Topics: Alendronate; Animals; Anti-Inflammatory Agents; Antimetabolites; Bone and Bones; Bone Resorption; Cl	2005
[To increase bone density faster and stronger]. MMW Fortschritte der Medizin, 2005, May-05, Volume: 147, Issue:18 Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter	2005
Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2005, Volume: 53, Issue:12 Topics: Acid Phosphatase; Actins; Alkaline Phosphatase; Animals; Animals, Newborn; Bone Density; Bone Resorp	2005
Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models. Rheumatology international, 2006, Volume: 26, Issue:7 Topics: Aged; Alkaline Phosphatase; Amino Acids; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone Densi	2006
Hospitalization-related bone loss and the protective effect of risedronate. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2006, Volume: 17, Issue:2 Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur	2006
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia. Journal of nutritional science and vitaminology, 2006, Volume: 52, Issue:1 Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metaboli	2006
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. Bone, 2006, Volume: 39, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density	2006
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone, 2006, Volume: 39, Issue:5 Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorpti	2006
Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid. Experimental animals, 2006, Volume: 55, Issue:4 Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption	2006
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats. Experimental animals, 2006, Volume: 55, Issue:5 Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Meta	2006
Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol. Journal of nutritional science and vitaminology, 2006, Volume: 52, Issue:6 Topics: Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Res	2006
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2007, Volume: 22, Issue:11 Topics: Access to Information; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic;	2007
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats. Journal of endocrinological investigation, 2007, Volume: 30, Issue:9 Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Mo	2007
Effect of etidronate on COX-2 expression and PGE(2) production in macrophage-like RAW 264.7 cells stimulated by titanium particles. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2007, Volume: 12, Issue:6 Topics: Animals; Bone Resorption; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase Inhibitor	2007
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy. Clinical biomechanics (Bristol, Avon), 2008, Volume: 23, Issue:3 Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Ani	2008
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone, 2008, Volume: 42, Issue:5 Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line, Tumor; Cell Surv	2008
Diphosphonates: aimed in a chemical sense. Lancet (London, England), 1981, Dec-12, Volume: 2, Issue:8259 Topics: Bone and Bones; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Etidronic Acid; Humans; M	1981
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet (London, England), 1984, Apr-14, Volume: 1, Issue:8381 Topics: Aged; Biopsy; Bone and Bones; Bone Resorption; Etidronic Acid; Female; Humans; Male; Middle Aged; Mi	1984
[Sodium etidronate (EHDP) and osteoporosis]. La Clinica terapeutica, 1981, Oct-15, Volume: 99, Issue:1 Topics: Adult; Aged; Bone Resorption; Calcium; Cyclic AMP; Etidronic Acid; Female; Humans; Hydroxyproline; M	1981
Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat. Cancer research, 1984, Volume: 44, Issue:7 Topics: Animals; Bone and Bones; Bone Resorption; Carcinoma 256, Walker; Clodronic Acid; Diphosphonates; Eti	1984
Effects of ethane-1-hydroxy-1,1-diphosphonate (EHDP) upon the kinetics of bone resorption and bone formation at the whole bone level in prelabelled chicks. Calcified tissue international, 1983, Volume: 35, Issue:4-5 Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Chickens; Collagen; Etidronic Acid; Femur; Kineti	1983
[Pseudosarcomatous osteolysis in a Paget's disease patient treated with disodium etidronate (EHDP)]. Revue du rhumatisme et des maladies osteo-articulaires, 1984, Volume: 51, Issue:1 Topics: Bone Neoplasms; Bone Resorption; Calcitonin; Diagnosis, Differential; Etidronic Acid; Humans; Male;	1984
Skeletal calcium homeostasis and countermeasures to prevent disuse osteoporosis. Calcified tissue international, 1984, Volume: 36 Suppl 1 Topics: Adult; Bed Rest; Bone and Bones; Bone Development; Bone Resorption; Calcitonin; Calcium; Etidronic A	1984
New diphosphonates to block bone resorption. The New England journal of medicine, 1980, Feb-07, Volume: 302, Issue:6 Topics: Animals; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Double-Blind Method; Eti	1980
Inhibition by two diphosphonates of bone lysis in tumor-conditioned media. Cancer research, 1981, Volume: 41, Issue:8 Topics: Animals; Bone Resorption; Clodronic Acid; Culture Media; Diphosphonates; Etidronic Acid; Indomethaci	1981
Parenteral diphosphonates for treating malignant hypercalcemia. Cancer, 1981, Oct-15, Volume: 48, Issue:8 Topics: Aged; Bone Neoplasms; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration	1981
[Treatment of hypercalcemia of tumoral origin with two diphosphonates]. Schweizerische medizinische Wochenschrift, 1980, Nov-29, Volume: 110, Issue:48 Topics: Adult; Aged; Bone Resorption; Bronchial Neoplasms; Diphosphonates; Esophageal Neoplasms; Etidronic A	1980
Steady-state relationship of calcium-45 between bone and blood: differences in growing dogs, chicks, and rats. Science (New York, N.Y.), 1981, Oct-09, Volume: 214, Issue:4517 Topics: Age Factors; Animals; Bone and Bones; Bone Development; Bone Resorption; Calcium; Calcium Radioisoto	1981
The long-term skeletal effects of EHDP in dogs. Metabolic bone disease & related research, 1981, Volume: 3, Issue:4-5 Topics: Animals; Biopsy; Bone and Bones; Bone Resorption; Dogs; Etidronic Acid; Female; Ribs; Time Factors	1981
Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone. Metabolic bone disease & related research, 1981, Volume: 3, Issue:4-5 Topics: Adult; Aged; Biopsy; Bone Resorption; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis De	1981
Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy. Mineral and electrolyte metabolism, 1982, Volume: 7, Issue:2 Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Resorption; Calcifediol; Calcium; Chronic Kidney D	1982
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:6 Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channe	1995
Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clinical chemistry, 1995, Volume: 41, Issue:11 Topics: Acid Phosphatase; Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Resorption; Chromatography,	1995
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer research, 1995, Aug-15, Volume: 55, Issue:16 Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid	1995
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats. Bone, 1995, Volume: 16, Issue:6 Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitoni	1995
Paget's disease of bone. Current therapy in endocrinology and metabolism, 1994, Volume: 5 Topics: Bone Resorption; Calcitonin; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans	1994
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:2 Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remode	1995
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy. Bone, 1995, Volume: 16, Issue:2 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Aci	1995
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model. Bone, 1995, Volume: 16, Issue:2 Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone	1995
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone, 1995, Volume: 16, Issue:2 Topics: Alendronate; Animals; Autoradiography; Bone and Bones; Bone Resorption; Calcium; Carbon Radioisotope	1995
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone, 1995, Volume: 16, Issue:2 Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, An	1995
Repair processes in the periodontium following dentoalveolar ankylosis: the effect of masticatory function. Journal of clinical periodontology, 1994, Volume: 21, Issue:7 Topics: Alveolar Process; Animals; Ankylosis; Bone Matrix; Bone Resorption; Dental Cementum; Dentin; Etidron	1994
A rat model of thyroid hormone-induced bone loss: effect of antiresorptive agents on regional bone density and osteocalcin gene expression. Thyroid : official journal of the American Thyroid Association, 1994,Spring, Volume: 4, Issue:1 Topics: Animals; Base Sequence; Bone Density; Bone Resorption; Calcitonin; Disease Models, Animal; DNA, Comp	1994
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1994, Volume: 9, Issue:2 Topics: Adenocarcinoma; Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Neoplasms; Bone Res	1994
Cyclic etidronate: has the rose lost its bloom? The American journal of medicine, 1993, Volume: 95, Issue:6 Topics: Bone Density; Bone Resorption; Drug Administration Schedule; Etidronic Acid; Humans; Spinal Fracture	1993
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. The Journal of clinical endocrinology and metabolism, 1993, Volume: 77, Issue:4 Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Bone Resorption; Calcium; Et	1993
Successful treatment of immobilization hypercalcemia using calcitonin and etidronate. Archives of physical medicine and rehabilitation, 1993, Volume: 74, Issue:3 Topics: Adolescent; Adult; Bone Resorption; Calcitonin; Drug Therapy, Combination; Etidronic Acid; Female; H	1993
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. The Journal of clinical investigation, 1993, Volume: 91, Issue:5 Topics: Alendronate; Animals; Animals, Newborn; Bone Resorption; Cell Line; Cells, Cultured; Clodronic Acid;	1993
A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone, 1995, Volume: 17, Issue:2 Topics: Animals; Bone Marrow; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Polarity; Cells, Cultured	1995
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1995, Volume: 10, Issue:11 Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal	1995
[Biphosphonates]. Revue medicale de Liege, 1996, Volume: 51, Issue:1 Topics: Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Diphosphonates; Etidronic Acid; Humans; O	1996
Bone loss after liver transplantation is not prevented by cyclical etidronate, calcium and alphacalcidol. The Liver Transplant Group, Groningen. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1996, Volume: 6, Issue:3 Topics: Absorptiometry, Photon; Adult; Biomarkers; Bone Density; Bone Resorption; Calcium; Creatinine; Etidr	1996
New biochemical markers of bone resorption derived from collagen breakdown in the study of postmenopausal osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 1996, Volume: 6, Issue:4 Topics: Adult; Aged; Amino Acids; Biomarkers; Bone Diseases, Metabolic; Bone Resorption; Calcium; Collagen;	1996
Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:10 Topics: Amines; Analysis of Variance; Animals; Binding Sites; Bone Matrix; Bone Resorption; Calcium Oxalate;	1996
The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1996, Volume: 11, Issue:10 Topics: Alendronate; Animals; Binding, Competitive; Bone Resorption; Cell Membrane Permeability; Chickens; D	1996
In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages. Journal of pharmaceutical sciences, 1997, Volume: 86, Issue:3 Topics: Animals; Bioprosthesis; Bone Resorption; Calcinosis; Carcinoma 256, Walker; Cell Line; Cell Survival	1997
A comparative study on biochemical markers of bone collagen breakdown in post-menopausal women. Pharmacological research, 1997, Volume: 36, Issue:3 Topics: Aged; Amino Acids; Biomarkers; Bone Resorption; Collagen; Estrogen Replacement Therapy; Etidronic Ac	1997
The effects of Didronel on osteoclastic resorption in Sprague-Dawley rat mandibles. Northwestern dental research, 1995,Fall, Volume: 6, Issue:1 Topics: Acridine Orange; Alkaline Phosphatase; Animals; Bone Resorption; Cells, Cultured; Dose-Response Rela	1995
Differential effects of aminosubstituted analogs of hydroxy bisphosphonates on the growth of Dictyostelium discoideum. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:2 Topics: Amines; Animals; Bone Density; Bone Resorption; Dictyostelium; Diphosphonates; Dose-Response Relatio	1998
Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. Journal of chromatography. B, Biomedical sciences and applications, 1997, Dec-19, Volume: 704, Issue:1-2 Topics: Adenine Nucleotides; Animals; Bone Resorption; Cell Line; Chromatography, High Pressure Liquid; Clod	1997
TRK-530 inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts. Pharmacology, 1998, Volume: 56, Issue:3 Topics: Animals; Animals, Suckling; Antioxidants; Bone Resorption; Calcitriol; Calcium Channel Blockers; Dip	1998
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1998, Volume: 13, Issue:4 Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; E	1998
Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats. Bone, 1998, Volume: 23, Issue:1 Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Calcium Cha	1998
Risedronate for Paget's disease of bone. The Medical letter on drugs and therapeutics, 1998, Aug-28, Volume: 40, Issue:1034 Topics: Administration, Oral; Aged; Bone Resorption; Calcium Channel Blockers; Clinical Trials as Topic; Dia	1998
Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Digestive diseases and sciences, 1998, Volume: 43, Issue:9 Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membr	1998
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone, 1998, Volume: 23, Issue:5 Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture	1998
Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 1998, Volume: 17, Issue:11 Topics: Absorptiometry, Photon; Amino Acids; Biomarkers; Bone Density; Bone Resorption; Calcitriol; Calcium;	1998
Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Annals of the rheumatic diseases, 1998, Volume: 57, Issue:10 Topics: Animals; Bone and Bones; Bone Cements; Bone Resorption; Cell Culture Techniques; Cell Differentiatio	1998
Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcified tissue international, 1999, Volume: 64, Issue:3 Topics: Actins; Animals; Animals, Newborn; Apoptosis; Bone Resorption; Cell Separation; Cells, Cultured; Den	1999
Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats. Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1998, Volume: 19, Issue:2 Topics: Animals; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Osteoporosis, Po	1998
The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2000, Volume: 15, Issue:5 Topics: Alendronate; Alkyl and Aryl Transferases; Amino Acid Sequence; Animals; Base Sequence; Bone Resorpti	2000
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. Journal of dental research, 2000, Volume: 79, Issue:6 Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates	2000
Drugs for prevention and treatment of postmenopausal osteoporosis. The Medical letter on drugs and therapeutics, 2000, Oct-16, Volume: 42, Issue:1090 Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calciton	2000
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology, 2000, Volume: 141, Issue:12 Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitor	2000
Once-a-week alendronate (Fosamax). The Medical letter on drugs and therapeutics, 2001, Mar-19, Volume: 43, Issue:1100 Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials a	2001
Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:5 Topics: Alendronate; Animals; Aortic Diseases; Bone Resorption; Calcification, Physiologic; Calcinosis; Diph	2001
[Fluorides and bisphosphonates in the treatment of osteoporosis]. Der Orthopade, 2001, Volume: 30, Issue:7 Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Dru	2001
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone, 2001, Volume: 29, Issue:6 Topics: Actins; Alendronate; Animals; Apoptosis; Bone Resorption; Cytoskeleton; Etidronic Acid; Mice; Osteoc	2001
Effect of etidronate on bone in orchidectomized and sciatic neurectomized adult rats. Bone, 2002, Volume: 30, Issue:2 Topics: Age Factors; Amino Acids; Animals; Body Weight; Bone Density; Bone Resorption; Denervation; Etidroni	2002
A cysteine protease inhibitor prevents suspension-induced declines in bone weight and strength in rats. Journal of physiological anthropology and applied human science, 2002, Volume: 21, Issue:1 Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Cathepsin K; Cathepsins; Collagenases; Cysteine P	2002
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats. Endocrinology, 2002, Volume: 143, Issue:7 Topics: Aging; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Ca	2002
Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2002, Volume: 17, Issue:7 Topics: Alendronate; alpha-Fetoproteins; Animals; Bone and Bones; Bone Remodeling; Bone Resorption; Calciton	2002
The comparative effects of dichloromethylene diphosphonate (C12MDP) and ethane-1-hydroxy-1,1-diphosphonate (EHDP) on growth and modeling of the rat tibia. Calcified tissue research, 1977, Oct-20, Volume: 23, Issue:3 Topics: Animals; Bone Development; Bone Resorption; Calcification, Physiologic; Clodronic Acid; Diphosphonat	1977
[Paget's disease of bone]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1979, Jan-10, Volume: 99, Issue:1 Topics: Aged; Bone Resorption; Calcitonin; Etidronic Acid; Female; Humans; Inclusion Bodies, Viral; Male; Mi	1979
Comparative antiinflammatory and bone protective effects of two diphosphonates in adjuvant arthritis. Arthritis and rheumatism, 1979, Volume: 22, Issue:4 Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Body Weight; Bone and Bones;	1979
Comparison of the effects of ethane-1-hydroxy-1,1-diphosphonate and dichloromethylene diphosphonate upon periodontal bone resorption in rice rats (Oryzomys palustris). Archives of oral biology, 1979, Volume: 24, Issue:9 Topics: Animals; Bone Resorption; Clodronic Acid; Etidronic Acid; Male; Mandible; Rodentia	1979
Effects of dichloromethylene diphosphonate, ethane-1-hydroxy-1,1-diphosphonate, and rickets in rats. The Journal of laboratory and clinical medicine, 1975, Volume: 86, Issue:5 Topics: Acetates; Animals; Bone and Bones; Bone Development; Bone Resorption; Calcinosis; Calcium; Diet; Eti	1975
Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. The American journal of pathology, 1976, Volume: 83, Issue:3 Topics: Animals; Antigens; Bone Resorption; Calcium; Calcium, Dietary; Cattle; Cattle Diseases; Cyclic AMP;	1976
Ethane-1-hydroxy-1, 1-diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calcified tissue research, 1977, Feb-11, Volume: 22, Issue:3 Topics: Animals; Autoradiography; Bone Resorption; Cell Count; Cell Differentiation; Etidronic Acid; Karyome	1977
Bone remodeling and calcium metabolism: a correlated histomorphometric, calcium kinetic, and biochemical study in patients with osteoporosis and Paget's Disease. Metabolism: clinical and experimental, 1977, Volume: 26, Issue:6 Topics: Adult; Aged; Bone and Bones; Bone Resorption; Calcium; Etidronic Acid; Female; Histocytochemistry; H	1977
Action of 1,25-dihydroxyvitamin D3 and a diphosphonate on calcium metabolism in rats. The American journal of physiology, 1975, Volume: 229, Issue:2 Topics: Animals; Bone Resorption; Calcium; Dihydroxycholecalciferols; Dose-Response Relationship, Drug; Epip	1975
Ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Effects on growth and modeling of the rat tibia. Calcified tissue research, 1975, Sep-05, Volume: 18, Issue:3 Topics: Animals; Bone and Bones; Bone Development; Bone Resorption; Calcification, Physiologic; Cartilage; E	1975
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1992, Volume: 7, Issue:9 Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption	1992
Effect of exercise and bisphosphonate on mineral balance and bone density during 360 day antiorthostatic hypokinesia. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1992, Volume: 7 Suppl 2 Topics: Adult; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Calcium; Combined Modality Therap	1992
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:9 Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic	1991
Bone matrix constituents stimulate interleukin-1 release from human blood mononuclear cells. The Journal of clinical investigation, 1991, Volume: 87, Issue:1 Topics: Animals; Antibodies, Monoclonal; Bone Matrix; Bone Resorption; Cell Adhesion; Cells, Cultured; Colla	1991
Application of reflected light microscopy to identify and quantitate resorption by isolated osteoclasts. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:7 Topics: Animals; Bone Resorption; Cattle; Chick Embryo; Diterpenes; Etidronic Acid; Histological Techniques;	1991
Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1991, Volume: 6, Issue:7 Topics: Adult; Bed Rest; Bone and Bones; Bone Resorption; Cell Count; Etidronic Acid; Humans; Male; Osteocla	1991
Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. The Journal of clinical investigation, 1990, Volume: 85, Issue:2 Topics: Animals; Bone Resorption; Cells, Cultured; Chickens; Diphosphonates; Etidronic Acid; Female; Osteocl	1990
Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1990, Volume: 5, Issue:1 Topics: Alendronate; Animals; Bone Resorption; Cattle; Cell Survival; Diphosphonates; Etidronic Acid; In Vit	1990
Inhibition of osteoclast recruitment at a local site by 1-hydroxyethylidene-1,1-bisphosphonate (HEBP). The Annals of otology, rhinology, and laryngology, 1990, Volume: 99, Issue:9 Pt 1 Topics: Air Pressure; Animals; Bone Resorption; Ear, Middle; Etidronic Acid; Gerbillinae; Male; Osteoclasts	1990
Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1989, Volume: 4, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Drug Administration Schedule; Drug Therapy	1989
Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. Metabolism: clinical and experimental, 1989, Volume: 38, Issue:9 Topics: Adult; Bone Resorption; Cell Count; Etidronic Acid; Humans; Immobilization; Male; Osteoclasts; Osteo	1989
NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. International journal of tissue reactions, 1989, Volume: 11, Issue:5 Topics: Animals; Arthritis; Arthritis, Experimental; Bone Resorption; Disease Models, Animal; Etidronic Acid	1989
[Effects of EDTPO on hard tissues in rats. 1. Comparison of histological changes produced by same molar of EDTPO, HEBP and EDTA]. Shigaku = Odontology; journal of Nihon Dental College, 1989, Volume: 77, Issue:2 Topics: Animals; Bone Resorption; Calcification, Physiologic; Diphosphonates; Edetic Acid; Etidronic Acid; G	1989
Bisphosphonates and extrarenal acid buffering capacity. Calcified tissue international, 1989, Volume: 44, Issue:1 Topics: Acid-Base Equilibrium; Animals; Bone and Bones; Bone Development; Bone Resorption; Buffers; Clodroni	1989
Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone, 1987, Volume: 8 Suppl 1 Topics: Alkaline Phosphatase; Biopsy; Bone and Bones; Bone Resorption; Clodronic Acid; Diphosphonates; Etidr	1987
Transient taste-loss during treatment with etidronate. Lancet (London, England), 1987, Sep-12, Volume: 2, Issue:8559 Topics: Ageusia; Bone Resorption; Etidronic Acid; Humans; Taste Disorders	1987
Histologic study of the inhibition of bone resorption in organ cultures by myo-inositol-2-monophosphate. Journal of oral pathology, 1986, Volume: 15, Issue:1 Topics: Animals; Bone and Bones; Bone Resorption; Clodronic Acid; Etidronic Acid; Fetus; Inositol Phosphates	1986
Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms. Advances in experimental medicine and biology, 1986, Volume: 208 Topics: Animals; Bone and Bones; Bone Resorption; Cell Differentiation; Chemotaxis; Clodronic Acid; Culture	1986
Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone, 1987, Volume: 8, Issue:3 Topics: Animals; Bone and Bones; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; In Vitro T	1987
An investigation of calcium intake, 1-alpha(OH)D3, and etidronate on bone. Bone, 1987, Volume: 8, Issue:2 Topics: Animals; Bone and Bones; Bone Resorption; Calcium; Calcium, Dietary; Cyclic AMP; Etidronic Acid; Fem	1987
[Pseudotumoral osteolysis caused by diphosphonates]. Revue du rhumatisme et des maladies osteo-articulaires, 1986, Volume: 53, Issue:4 Topics: Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Osteitis Deformans; Osteolysis; Radiog	1986
Effect of diphosphonate on the prevention of X-radiation-induced inhibition of bone formation in rats. Journal of oral pathology, 1986, Volume: 15, Issue:9 Topics: Alveolar Process; Animals; Bone Resorption; Etidronic Acid; Granulation Tissue; Male; Mandible; Oste	1986
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:1 Topics: Aged; Biopsy; Bone Neoplasms; Bone Resorption; Calcitonin; Carcinoma; Etidronic Acid; Humans; Ilium;	1987
A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium. Journal of cancer research and clinical oncology, 1987, Volume: 113, Issue:6 Topics: Animals; Bone Neoplasms; Bone Resorption; Etidronic Acid; Mice; Neoplasm Transplantation; Neoplasms,	1987
Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. The Journal of clinical endocrinology and metabolism, 1988, Volume: 66, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Resorption; Calcium Carbonate; Drug Therapy, Co	1988
Effects of a 120 day period of bed-rest on bone mass and bone cell activities in man: attempts at countermeasure. Bone and mineral, 1987, Volume: 2, Issue:5 Topics: Adult; Bone and Bones; Bone Development; Bone Resorption; Etidronic Acid; Exercise; Humans; Immobili	1987
Prevention of post-irradiation alveolar bone resorption by diphosphonate. Acta odontologica latinoamericana : AOL, 1986, Volume: 3, Issue:1-2 Topics: Alveolar Process; Animals; Bone Resorption; Etidronic Acid; Radiation Injuries, Experimental; Rats;	1986
Diphosphonates for otospongiosis. The American journal of otology, 1985, Volume: 6, Issue:1 Topics: Adult; Bone Development; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Ma	1985
[Hypercalcemia with elevation of parathormone in lymphocytic lymphoma. Efficacy of ethanehydroxydiphosphonate by mouth]. Annales de medecine interne, 1985, Volume: 136, Issue:2 Topics: Bone Resorption; Etidronic Acid; Female; Humans; Hypercalcemia; Lymphocytes; Lymphoma; Middle Aged;	1985
Treatment of Paget's disease of bone. Lancet (London, England), 1973, May-12, Volume: 1, Issue:7811 Topics: Animals; Bone Resorption; Calcitonin; Dactinomycin; Etidronic Acid; Glucagon; Humans; Osteitis Defor	1973
Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment. The Quarterly journal of medicine, 1973, Volume: 42, Issue:166 Topics: Adult; Aged; Alkaline Phosphatase; Biopsy; Bone Resorption; Calcitonin; Calcium; Clinical Enzyme Tes	1973
Proceedings: Some effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium metabolism in man. Clinical science and molecular medicine, 1974, Volume: 47, Issue:3 Topics: Bone Resorption; Calcium; Etidronic Acid; Humans; Organophosphorus Compounds	1974

etidronate and Bone Loss, Osteoclastic